Novavax Says Taiwan Grants EUA For Nuvaxovid XBB.1.5 Dispersion For Injection COVID-19 Vaccine
Novavax, Inc. (NVAX) announced Monday that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.